Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvements in Friedreich ataxia patients.read more...
Benzinga·3d ago
More News
Nasdaq Down 200 Points; Brady Earnings Top Views
US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs...
Benzinga·3d ago
Jim Cramer on Design Therapeutics: Pure Spec, Pure Spec
Jim Cramer on Design Therapeutics: Pure Spec, Pure Spec...
Yahoo! Finance: News·4d ago
Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock
Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares declined 0.8% to close at $95.43.read more...
Benzinga·6d ago
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·10d ago
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Design Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·20d ago
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 13.5% - Should You Sell?
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 13.5% - What's Next...
MarketBeat·21d ago
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High Following Earnings Beat
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year High Following Earnings Beat...
MarketBeat·22d ago
Design Therapeutics Q1 Earnings Call Highlights
Design Therapeutics (NASDAQ:DSGN) outlined its strategy and trial design for DT-216 in Friedreich's ataxia (FA), emphasizing that its ongoing RESTORE-FA multiple ascending dose study is intended to determine whether the therapy can meaningfully increase endogenous frataxin levels and help define a p...
Design Therapeutics (NASDAQ:DSGN - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.36) by...